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Abstract 
 
We studied the effects of ethanolic leaf extract of Azadirachta indica 
(AIE) on hepatic microscopic anatomy and oxidative stress markers in 
diabetic rats. Seventy-five Wistar rats (8 weeks old) were randomly 
assigned to five treatment groups: control; diabetic; diabetic+AIE; AIE 
only; and diabetic+glibenclamide. Hyperglycemia was induced in fasted 
rats with streptozotocin. AIE was administered orally at 500 mg/kg bw/d 
and glibenclamide at 600 μg/kg bw/d for 50 days (50 d). Animals were 
sacrificed on treatment days 7, 21 and 50. The liver was stained with PAS. 
Hepatic markers of oxidative stress were also estimated. At 50 d, 
histological study of the liver of diabetic rats showed swollen PAS+ 
hepatocytes, whose content was confirmed to be glycogen. On the 
contrary, hepatocytes of AIE-treated diabetic rats lacked glycogen. The 
major finding in these rats was exacerbated oxidative stress. Our findings 
in this model showed the beneficial effect of AIE in the amelioration of 
diabetic hepatic glycogenosis.  
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Introduction 
Diabetes mellitus describes a metabolic disorder of 
multiple etiologies. It is characterised by chronic 
hyperglycemia, with perturbations of carbohydrate, 
lipid and protein metabolism that result from 
defects in insulin secretion, insulin action or both 
[1]. Type 1 diabetes is a chronic auto-immune 
disease characterised by immune-mediated 
destruction of the insulin-producing β cells of 
pancreatic islets, resulting in absolute insulin 
deficiency. More than 90% of diabetics have type 2 
form of the disease. This is characterised by insulin 
resistance in otherwise insulin-sensitive cells [2].  
Efforts are ongoing to evaluate botanical drugs for 
the management of diabetes mellitus [3]. Herbs 
with potential antidiabetic property include 
Azadirachta indica A. Juss (neem). Currently, neem 
is included in antidiabetic formulations and food 
supplements. Such botanical formulations, 
including pancreatic tonic® and cogent db®, had 
been subjected to controlled clinical trials in the 
USA [4] and Malaysia [5], respectively, with 
promising results.  
doi:10.5138/ijpm.2010.0975.0185.02045 
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However, while botanical drugs are undoubtedly 
potential sources of new chemical entities in the 
management of diabetes and its complications, 
basic and clinical studies directed especially at their 
efficacy, safety and standardisation are inevitable 
[6]. Herbal drugs such as Aristolochia spp are 
associated with nephropathy owing to the presence 
of toxic aristolochic acid [7]. Pennyroyal oil from 
Mentha pulegium could induce liver damage and 
renal toxicity [8]; while hepatic toxicity is 
associated with the diterpenoid-containing herbal 
drug, Teuchrium chamaedrys [9].  
 
The liver is a central organ in glucose homeostasis; 
and it is involved in the complications of diabetes 
mellitus. While non-alcoholic fatty liver disease 
(NAFLD) may also be associated with type 1 
diabetes [10], hepatic histopathology in type 1 
diabetic patients could be distinct from type 2. 
Liver biopsy findings in type 1 diabetics with 
hepatomegaly are comparable to findings in 
Mauriac’s syndrome, and is characterised by 
excessive glycogen deposition in hepatocytes 
[10,11]. Poorly-controlled blood glucose has been 
associated with this form of glycogenosis.  
 
Moreover, hyperglycemia of diabetes is associated 
with oxidative stress; and the latter is involved in 
the etiology of diabetes complications [12]. 
Excessive glucose delivered to the mitochondria 
overdrives the electron transport chain, resulting in 
overproduction of superoxide anion [13]. 
Autoxidation of glucose in the presence of 
transition metals, and non-enzymatic glycation of 
proteins, also generate reactive oxygen species 
(ROS) in diabetes [14]. Besides, hyperglycemia can 
lower the activity of antioxidant enzymes such as 
SOD and glutathione reductase, perhaps by 
glycation [15]. Glutathione synthesis was also 
reported to be inhibited under hyperglycemic 
conditions [16].  
 
However, studies on the structural and biochemical 
changes in the liver of laboratory animals on AIE 
therapy have been poorly documented. Thus, the 
objectives of this work were to study (i) the 
potential hypoglycemic activity of AIE; and (ii) the 
histology and oxidative stress markers of the liver 
of streptozotocin-induced diabetic Wistar rats 
treated with AIE.  
Materials and Methods  
Animals  
Seventy-five male Wistar rats (Harlan, Milan, Italy) 
were used. Animals weighed 175.5 g on average 
and were 8 weeks old. Animals were housed in the 
animal holdings of the Faculty of Biological and 
Environmental Sciences and Technology, 
University of Salento, Italy. They were exposed to 
12-hour light, 12-hour dark cycle at a room 
temperature of 21-23 oC. All animals were 
maintained on Harlan Global Diet 2018 (Harlan, 
Milan, Italy). Both feed and water were given 
freely. Besides, animal handling and experimental 
procedures conformed to standard principles.  
 
Collection and extraction of Azadirachta indica 
leaves  
Mature fresh leaves of A. indica (A. Juss) were 
collected from A. indica trees in the premises of the 
University of Ilorin, Mini Campus, Nigeria, 
between June and August 2007. A sample of the 
collection was identified and compared with the 
voucher specimen at the herbarium of the Botany 
Department of the same University (Voucher No 
542). A. indica leaves were air-dried (at room 
temperature) and extracted by percolation as 
described by Chattopadhyay [17]. A total of 2.4 kg 
of the dry leaf powder was extracted at room 
temperature using 70% ethanol. The initial hydro-
alcoholic filtrate was concentrated under vacuum in 
a Buchi Rotavapor R-114 (Buchi, Switzerland) at 
50 oC (bath temperature). The concentrate was 
dissolved in distilled water and filtered with 
Whatman No.1 paper. The filtrate was concentrated 
in the rotavapor at 50 oC bath temperature. The 
final residue (about 120 g) was stored at 4 oC.  
 
Induction of diabetes mellitus  
Hyperglycemia was induced in 45 overnight-fasted, 
randomly-selected animals, by a single 
intraperitoneal injection of 70 mg/kg bw 
streptozotocin (Sigma, MO, USA) in 0.1 M citrate 
buffer, pH 4.5 [18]. Animals were allowed free 
access to feed and water after the injection. 
Hyperglycemia was allowed to develop over a 
minimum period of 72 hours [19]. Animals with 
fasting blood glucose ≥250 mg/dl were considered 
hyperglycemic [20]. Non-diabetic control animals 
(n=9) received a single intraperitoneal injection of 
0.1 M citrate buffer (1 ml/kg b w), pH 4.5.  
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Azadirachta indica treatment 
The dose of A. indica used was based on the work 
of Chattopadhyay [17]. Water-soluble, ethanolic 
extract of A. indica (AIE) (500 mg/kg bw/d) was 
administered by gavage to a group of 
hyperglycemic rats (n=15) at 9.00-10.00 hour each 
day for a maximum of 50 d. An antidiabetic drug, 
glibenclamide (Sigma, MO, USA), was also 
administered orally at 600 μg/kg bw/d [21] to 
another group of hyperglycemic rats (n=15), to 
allow for comparative studies. Furthermore, a 
separate group of normoglycemic rats (n=15) were 
administered 500 mg/kg b. w/d of AIE for the same 
period. Fifteen hyperglycemic rats, which received 
neither AIE nor glibenclamide, constituted the 
untreated diabetic group.  
 
Estimation of blood glucose  
Blood glucose was estimated in overnight-fasted 
rats at 9.00-10.00 hour by the glucose oxidase 
method, using One Touch Ultra 2 Glucometer 
(Lifescan, CA, USA). Blood was obtained from the 
dorsal vein of the tail. In the first week of treatment, 
blood glucose was monitored daily; thereafter, 
glucose levels were assessed at 72-hour interval.  
 
Body weight  
The body weights of the rats were taken prior to the 
induction of hyperglycemia, at day 0 of AIE and 
glibenclamide treatment, and at 72-hour interval 
thereafter.  
 
Termination of treatment  
For the purpose of assessing the biochemical and 
morphological changes occurring in the animals 
with the progression of treatment, 5 rats were 
sacrificed in each treatment group at the 7th, 21st, 
and 50th days of treatment. Animals were 
anaesthetized with pentobarbital (60 mg/ kg bw). 
Laparatomy was performed and the liver was 
excised, rinsed in PBS and fixed in Bouin’s fluid 
for histological studies. Portions of the liver were 
also stored at -80 oC for analysis of oxidative stress 
markers.  
 
Tissue processing for light microscopy  
After fixation, the liver was rinsed repeatedly in 
PBS until the yellowish coloration disappeared. 
Paraffin embedding was done, and 3.5 μm sections 
were cut on a Reichert-Jung 2050 rotary microtome 
(Cambridge Instruments, Germany), followed by 
Periodic acid-Schiff (PAS) staining. Briefly, 
sections were de-waxed in xylene, hydrated in 
descending grades of ethanol and then transferred 
to 0.8 % periodic for 10 min. Rinsing was done in 
ordinary water (10 min.), followed by exposure to 
Schiff reagent (30 min). After rinsing in ordinary 
water (20 min.), sections were stained in Carazzi’s 
haematoxylin (15 min) and eosin Y (1 min.). 
Photomicrographs were taken with a Nikon digital 
camera DXM1200F (Nikon, Japan) coupled to a 
Nikon Eclipse 80i light microscope (Nikon, Japan).  
 
Oxidative stress markers  
The levels of lipid hydroperoxides, aqueous 
hydroperoxide (hydrogen peroxide), reduced 
glutathione (GSH), and superoxide dismutase 
(SOD) were estimated in homogenates of the liver. 
For each sample, 10% homogenate was prepared 
with 0.15 M KCl as homogenizing buffer. The 
homogenate was centrifuged at 1000 g for 10 min 
at 4 oC [22]; and the supernatant was analysed for 
total protein and the markers of oxidative stress 
(except GSH).  
 
Hepatic lipid hydroperoxides  
Lipid hydroperoxide levels of each liver sample 
were estimated with a PeroxiDetectTM kit (Sigma, 
MO, USA). The assay was based on the oxidation 
of Fe2+ to Fe3+ by lipid hydroperoxides in the 
sample; Fe3+ then forms a coloured adduct with 
xylenol orange. This adduct is detectable by 
spectrophotometry at 560 nm. 
 
Hepatic aqueous hydroperoxide  
Aqueous hydroperoxide levels of each liver sample 
were estimated using PeroxiDetectTM kit (Sigma, 
MO, USA). The principle was as described for lipid 
hydroperoxides. However, colour formation was 
enhanced by the addition of sorbitol. Sorbitol is 
converted by H2O2 in the samples to a peroxyl 
radical. The latter oxidises Fe2+ to Fe3+, which then 
forms a coloured adduct with xylenol orange. 
Absorbance was read at 560 nm in an Ultraspec 
4000 UV/visible spectrophotometer (Pharmacia 
Biotech, Uppsala, Sweden).  
 
Reduced glutathione (GSH)  
GSH levels in liver samples were estimated with a 
glutathione assay kit (Sigma, MO, USA). The 
samples were homogenised with 5% sulphosalicylic 
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acid (5% SSA). The homogenates were allowed to 
stand for 10 min at 4 oC, and then centrifuged at 
10,000 x g for 10 minutes. The supernatants were 
diluted and used in the assay. Absorbance was read 
at 412 nm in a spectrophotometer.  
 
Protein assay  
Protein levels of the samples were estimated by the 
BioRad Protein Assay Method (BioRad, CA, USA). 
Bovine serum albumin (100 μg/ml) served as 
standard, and absorbance was read at 595 nm in an 
Ultraspec 4000 UV/visible spectrophotometer 
(Pharmacia Biotech, Uppsala, Sweden).  
 
Statistical analysis  
Data were analysed using SPSS 15.0 (SPSS Inc, 
Chicago, USA) and Excel 2007 (Microsoft 
Corporation, USA). Data were expressed as 
Mean±SEM, while means were compared using 
one way analysis of variance (ANOVA), and the 
Bonferroni post-hoc test. 
 
Results  
Body weight  
At the end of week 1, 1.5% loss in body weight had 
occurred in the AIE-treated diabetic rats. Similarly, 
body weight gain in the AIE-treated non-diabetic 
rats was negligible (Fig. 1). In contrast, relatively 
higher increases in body weight were obtained in 
the control, untreated diabetic and glibenclamide-
treated diabetic rats by this time (7 d). By 50 d, 
weight gain in the AIE-treated non-diabetic rats 
remained the least (19.9%), while the highest 
weight increase of 49.9% (P<0.05) occurred in the 
glibenclamide-treated rats (Fig. 1).  
 
 
Figure 1: Change (%) in body weights of animals at days 
7, 21, and 50 of treatment. Bar represents mean±SEM of 5 
animals. *P<0.05. (Glib. = Glibenclamide). 
Blood glucose  
Figure 2 shows details of blood glucose levels. At 
week 0, all animals in the diabetic, AIE-treated 
diabetic and glibenclamide-treated diabetic groups 
were hyperglycemic. By the end of week 1, 87.5% 
of the hyperglycemic rats treated with 500 mg/kg b 
w/d of AIE had become normoglycemic, and their 
blood glucose was therefore not significantly 
different from control (P>0.05). By the end of week 
2, normoglycemia had been established in all 
animals in this group. In hyperglycemic rats treated 
with glibenclamide (600 μg/kg bw/d), 100% of the 
animals remained hyperglycemic at 7 d. By week 3, 
all the rats in this group had become 
normoglycemic (Fig. 2); and this status was 
maintained till euthanasia. In contrast, all rats in the 
untreated diabetic group were hyperglycemic from 
week 0 to 7 (Fig. 2).  
 
 
Figure 2: Weekly blood glucose of control and treated 
animals. Bar represents mean±SEM. *P<0.05. (Glib. = 
Glibenclamide). 
 
Lipid hydroperoxide levels of the liver  
Figure 3 A shows changes (%) in lipid 
hydroperoxide levels of the different treatment 
groups compared with control. In the untreated 
diabetic rats, hepatic lipid hydroperoxide levels had 
increased significantly by 21 d and 50 d (p<0.05) 
(Fig. 3). Treatment of diabetic rats with AIE 
exacerbated hepatic oxidative stress (by 7 d) 
compared with control (P<0.05). In the latter phase 
of treatment, hepatic lipid hydroperoxide levels in 
these diabetic rats remained significantly higher 
than control (P<0.05). (Fig. 3 A).  
Furthermore, glibenclamide treatment did not 
prevent the rise in lipid peroxide levels in the 
diabetic rats. In these animals, lipid hydroperoxide 
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ps 
).  
levels 
e control at 7 d, to nearly 50% at 50 d (Fig. 3 
B).  
levels increased gradually from 31% above control 
at 7d, to 44% at 50d. Thus, at the latter phase of 
treatment, hepatic lipid hydroperoxide levels were 
significantly higher than control in all the grou
except AIE-treated normoglycemic rats (Fig. 3
 
Aqueous hydroperoxide levels of the liver  
Hepatic aqueous hydroperoxide levels are shown in 
figure 3 B. In the control rats, aqueous 
hydroperoxide levels remained nearly constant 
throughout the study period. In the untreated 
diabetic group, aqueous hydroperoxide levels were 
similar to control at 7 d. At 50 d, significant 
increases in hepatic aqueous hydroperoxide 
of these animals had had occurred (P<0.05).  
Similarly, hepatic aqueous hydroperoxide levels in 
the AIE-treated diabetic rats did not differ 
significantly from control at 7 d. However, by 50 d, 
the levels had increased, and was nearly 60% above 
control (P<0.05). Moreover, glibenclamide 
treatment could not prevent the rise in aqueous 
hydroperoxide levels. In these animals, aqueous 
hydroperoxide levels rose from as low as 15% 
abov
 
 
Figure 3: (A) Lipid hydroperoxide levels of the liver. Bars 
represent Mean±SEM of 5 animals. (B) Aqueous hydroperoxide 
levels of the liver. Bars represent Mean±SEM of 5 
5) to a level 20% below control 
at 50 d (Fig. 4 B).  
animals;*P<0.05. 
 
Superoxide dismutase (SOD) activity of the liver  
Hepatic SOD activities are shown in figure 4 A. By 
7 d, liver SOD activity had decreased significantly 
by 42% in the diabetic rats compared with control 
(P<0.05). SOD activities in hyperglycemic rats 
treated with AIE were however not significantly 
different from control (P<0.05). At 50 d, SOD 
activities in all the treatment groups did not differ 
statistically from control, except for the AIE-treated 
normoglycemic rats, where a significant decrease 
had occurred (Fig. 4 A).  
 
Hepatic reduced glutathione (GSH)  
Hepatic GSH levels are shown in figure 4 B. 
Cellular GSH levels decreased progressively in the 
untreated diabetic rats from a 3-fold increase above 
control at 7 d (P<0.05), to a level 5% below control 
at 50 d. Similarly, GSH levels in AIE-treated 
diabetic rats decreased from a level 58% above 
control at 7 d (P>0.0
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er. Bars represent Mean±SEM of 5 
e glibenclamide-treated 
ytes were characterised by 
the presence of multivesicular intracytoplasmic 
vacuoles (Fig. 5 E and F).  
Figure 4: (A) SOD activity of the liv
animals. (B) GSH levels of the liver. Bars represent Mean±SEM of 5 
animals; *P<0.05. 
 
Hepatic histopathology  
At 50 d of treatment, liver sections of untreated 
diabetic rats showed changes characteristic of 
hepatic glycogenosis (Fig. 5 C). Hepatocytes were 
swollen and strongly PAS-positive. This PAS 
positive-staining was observed in the cytoplasm of 
hepatocytes, and this finding suggests glycogen 
accumulation. Diastase digestion of the sections 
however resulted in loss of the PAS-positive 
staining (Fig. 5 D), thereby confirming the presence 
of glycogen in hepatocytes. Besides, the central 
veins of these untreated diabetic animals were 
compressed and congested, while sinusoids were 
either occluded or compressed and congested. 
Portal areas were rarely discernible, and so were 
Kupffer cells. In contrast, such histological findings 
were absent in AIE-treated diabetic rats. The major 
finding in these animals was mild lobular 
inflammation (Fig. 5 B). Apart from this, hepatic 
morphology in this group was comparable to 
control (Fig. 5 A). In th
diabetic group, hepatoc
 
  
  
  
28 Figure 5 (A-H): Hepatic histopathology at 50d. (A) Control group. 
Cords of hepatocytes appear distinct and sinusoids (S) remain patent; P, 
portal area. Hepatocytes are PAS–. (B) Neem-treated diabetic group; 
aggregates of leucocytes (arrows) are observable. (C&D) Diabetic group. 
C shows swollen and strongly PAS+ hepatocytes. Sinusoids are either 
occluded or compressed and congested. (D) The same tissue as in C, after 
astase digestion, showing PAS– staining that confirms the presence of 
C. (E&F) Glibenclamide-treated diabetic group. 
salivary gland of 
rom the use of an isolated 
di
glycogen in section 
Multivesicular intracytoplasmic vacuoles are seen in hepatocytes. Periodic 
acid-Schiff; x60; Bar is 10 μ. 
 
Discussion  
In this study, ethanolic extract of the leaves of 
Azadirachta indica (AIE), administered at 500 
mg/kg bw/d to hyperglycemic rats, produced 
normoglycemia in the larger percentage of the 
animals by the end of week 1 of treatment (Fig. 2). 
This hypoglycemic effect of AIE corroborates 
previous findings in dogs [23], rabbits [24], and rats 
[17]. Reported mechanisms of hypoglycemic effect 
of AIE include inhibition of adrenalin-induced 
glycogenolysis [25], and an insulinotropic effect 
[17]. However, in the present study, we observed a 
modulatory effect of AIE on body weight in 
diabetic and non-diabetic rats. By 50 d, gain in 
body weight was least in the AIE-treated rats (Fig. 
1). This suggests a modulatory effect of AIE on 
leptin production and/or action, or some effect on 
body adiposity. The findings of Szayna et al [26] 
reported such a mechanism for the antidiabetic 
activity of exendin-4 from the 
Gila monster lizard. Further study is therefore 
required in this direction with respect to the 
hypoglycaemic activity of AIE.  
A plethora of phytochemicals is derivable from 
neem leaf [27]. Among these, quercetin, myricetin, 
kaemferol, and their glycosides, have been 
implicated as contributing to the antidiabetic effect 
of neem leaf [17]. However, Sanders et al [28] and 
Dias et al [29] reported negative effect of quercetin 
on blood glucose in STZ-induced hyperglycemic 
rats treated with 10 mg/kg bw/d and 150 μmol /kg 
bw/d of quercetin respectively. This suggests that 
phytochemicals other than flavonoids may be 
responsible for, or contribute to the hypoglycemic 
property of neem. Besides, it is possible that the 
negative findings of Sanders et al [28] and Dias et 
al [29] might arise f
flavonoid (quercetin). Synergic activity of all 
bioflavonoids in neem may account for its 
hypoglycemic effect.  
In this work, we report hepatic glycogenosis 
(glycogenic hepatopathy) in diabetic rats induced to 
hyperglycemia with STZ (70 mg/kg bw). At 
euthanasia (50 d after attainment of 
hyperglycemia), hepatocytes were glycogen-laden, 
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 glycogenosis 
etes. Besides, the work of 
0 d was 
as shown by their strong PAS-positive staining 
(Fig. 5 C). Hepatic glycogenosis had been reported 
as a common complication in type 1 diabetics 
whose blood glucose is poorly-controlled with 
insulin [10,11]. Up to 80% of type 1 diabetes 
patients could be affected [30]. In such patients, 
marked accumulation of glycogen occurs in 
hepatocytes when insulin treatment leads to 
increased uptake of glucose by hepatocytes, 
followed by rapid conversion of glucose to 
glycogen, and subsequently, trapping of the latter 
[31]. Apart from diabetes, hepatic
could also occur in Mauriac’s syndrome [32], 
glycogen storage disease [33], and following short-
term high dose steroid therapy [34].  
In this work, accumulation of glycogen in 
hepatocytes of diabetic rats might arise from 
upregulation of glycogen synthase. This enzyme 
had been shown to be upregulated in alloxan- and 
STZ-induced diabetes [35,36]. In the latter model, 
total glycogen synthase was reported to be 
significantly higher than control 40 d after 
induction of diab
Ferrannini et al [37] showed that longstanding 
insulin deficiency might actually enhance glycogen 
synthase activity.  
Clinical management of diabetic hepatic 
glycogenosis include administration of short- and 
intermediate-acting insulin [38], psychological 
support and dietary control [10], and pancreas 
transplantation [39]. Our finding in this study 
suggests that AIE could ameliorate hepatic 
glycogenosis when used as an antidiabetic therapy. 
The marked glycogen accumulation observed in the 
hepatocytes of untreated diabetic rats at 5
absent in those diabetic rats treated with AIE. This 
beneficial effect might arise from effective control 
of blood glucose by this botanical extract.  
However, though hepatocytes of AIE-treated 
diabetic rats were devoid of glycogen, one 
characteristic histological finding in these rats (at 
50 d) was the presence of aggregates of leucocytes 
in hepatic sinusoids (Fig. 5 B). This suggests mild 
lobular inflammation of the liver in these animals, 
and the development might be associated with 
hepatic oxidative stress observed throughout the 
study (Fig. 3A and 3B). The high levels of hepatic 
lipid peroxidation products in the untreated diabetic 
rats treated with AIE suggest increased formation 
of reactive oxygen species (ROS) in hepatocytes, 
and perhaps in other hepatic cells, such as 
sinusoidal endothelial and Kupffer cells. The work 
of Vischer et al [40] showed that high levels of 
ROS in vascular endothelial cells could stimulate 
exocytosis of Weibel-Palade bodies, and thus, 
expression of selectin platelet (SELP) on the 
surface of these cells. High ROS levels in 
sinusoidal endothelial cells could also enhance the 
transcription of SELP and other adhesion molecules 
via the activation of the redox-sensitive NFkB. 
Expression of SELP on hepatic sinusoidal 
endothelial cell surface could mediate the tethering 
and adherence of leucocytes to vessel surface, 
leading to the aggregation of these cells [41,42]. 
This phenomenon could explain the aggregation of 
leucocytes in hepatic sinusoids of AIE-treated 
diabetic rats. A similar finding was reported by 
Chosay et al [43] in endotoxin-induced liver injury.  
As shown in figures 3 A and 3 B, significant 
increases in hepatic lipid hydroperoxide and H2O2 
levels occurred in the untreated diabetic and AIE-
treated diabetic rats throughout the 50-day 
treatment period. In the untreated diabetic rats, 
hepatic oxidative stress could be a result of chronic 
hyperglycemia, as explained elsewhere [13,14,16]. 
However, the high hepatic lipid hydroperoxide and 
aqueous hydroperoxide levels obtained in the AIE-
treated diabetic and AIE-treated non-diabetic rats, 
largely in the absence of hyperglycemia, may not 
be readily explainable. A probable source of high 
ROS in these animals could be hepatic metabolism 
of AIE by the cytochrome P450 enzymes. The P450 
families play active roles in the metabolism of 
drugs and xenobiotics [44]. Their induction and 
activity have been associated with enhanced ROS 
production [45]; and this suggests that certain 
phytochemicals in neem could induce some of these 
enzymes. Such induction may result in increased 
generation of ROS. Previous findings had reported 
such an association between hepatic metabolism of 
drugs/xenobiotics by cytochrome P450, and ROS 
generation. For example, the toxic effects of 2, 3, 7, 
8-tetrachlorodibenzo-p-dioxin was reported to arise 
from ROS generation via induction of the P450 
enzymes [46]. Ethanol could also induce certain 
families of P450 to produce free radicals [47]. The 
work of Dasgupta et al [48] showed that 80% 
ethanolic leaf extract of neem, administered to mice 
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ts. 
 hepatitis [50] and 
ggest that the herb 
ide) is an insulin secretagogue. Thus, 
at a dose of 200 mg and 500 mg/kg bw/d, could 
induce the phase II enzymes, which are involved in 
the metabolism of xenobiotics. Thus, generation o
reactive oxygen species, which may arise from such 
cellular activities, could account for the high 
hepatic lipid peroxidation obtained in our model.  
However, in non-diabetic rats treated with AIE, 
increases in hepatic lipid peroxidation products 
were limited to the early periods of exposure (Fig. 
3A and 3B). Levels of these products were 
significantly lower than control at 50 d, in contrast 
to AIE-treated diabetic rats, where ROS remained 
significantly high throughout exposure period. This 
implies that AIE-associated ROS generation was 
limited to the early phase of AIE treatment. Thus, 
the significant reduction in hepatic lipid 
hydroperoxide levels in AIE-treated non-diabetic 
rats (at 50 d) suggests that certain mechanisms were 
induced in the liver to suppress ROS generation (or 
scavenge these molecules) with continued exposure 
to AIE; and that such mechanisms were either 
inhibited or overwhelmed in the AIE-treated 
diabetic rats. One mechanism that could be 
involved in the suppression of ROS generation (or 
accumulation) in AIE-treated non-diabetic rats was 
upregulation of the antioxidant system. However, 
our findings in these animals showed that SOD and 
GSH levels were significantly lower than control 
(at 50 d) (Fig. 4 A & B). This suggests that the 
reduced ROS levels in these animals might arise 
from reduced generation of ROS, rather than 
enhanced scavenging activity by antioxidan
Down regulation of the cytochrome P450 enzymes 
in the latter phase of neem exposure might thus be 
responsible, but this is subject to further studies.  
Furthermore, the significantly high hepatic lipid 
hydroperoxide levels in AIE-treated diabetic rats (at 
50 d) could arise from ROS generation by 
leucocytes seen in higher number in the liver at this 
time. Leucocytes generate free radicals as part of 
their defensive mechanisms [49]. But they have 
been reported to produce significantly high amounts 
of ROS in experimental
pancreatitis [51]. In the present study, AIE could 
not prevent the generation of such high levels of 
hepatic ROS in these cells.  
Most previous studies of the antioxidant activity of 
neem reported positive findings based on the high 
flavonoids content of this plant; and 
phytochemicals such as quercetin and rutin have 
been mostly implicated [52]. However, reports from 
in vivo studies of the antioxidant effect of quercetin 
in STZ diabetic rats had been conflicting. 
Suppression of hepatic oxidative stress was 
reported by Dias et al [29], while Sanders et al [28] 
did not observe this. In the present study, the 
persistently high hepatic lipid hydroperoxide levels 
and the influx of leucocytes into the liver of 
diabetic rats treated with AIE su
may not possess antioxidant activity in the liver; 
and that long-term treatment with AIE could be 
associated with hepatic injury.  
Furthermore, hepatocellular ballooning, 
characterised by the presence of multivesicular 
intracytoplasmic vacuoles, were seen at 50 d in all 
zones of hepatic acini in diabetic rats treated with 
glibenclamide. However, such vacuoles were not 
observed in the other treatment groups. In diabetic 
patients, gross liver enlargement and ballooning of 
hepatocytes are generally interpreted as steatosis or 
steatohepatitis, arising from impaired hepatic lipid 
metabolism. The development of a steatotic liver in 
diabetes is associated with decreased plasma insulin 
levels, and thus, increased lipolysis [53]. Such 
metabolic perturbations could imply increased 
delivery of exogenous fatty acids to hepatocytes; 
increased endogenous hepatic production of fatty 
acids; decreased hepatic disposal of fatty acids; or 
impaired export of VLDL from the liver. These can 
thus lead to hepatic accumulation of lipids, 
especially in type 2 diabetic patients [54]. In the 
present study, Sudan black staining of the ballooned 
hepatocytes did not confirm the presence of lipid in 
the vacuoles; and this suggests absence of steatosis. 
This could be expected as the administered drug 
(glibenclam
improved levels of insulin in these animals not only 
restored normoglycemia but also suppressed 
lipolysis.  
Moreover, vacuolation and ballooning of 
hepatocytes had also been associated with anoxia 
that may occur at euthanasia [55]. Trowell [56] 
observed hepatic vacuolation from 5-15 minutes 
after death of animals from anoxia or asphyxia; 
while Sykes et al [57] reported marked hepatocyte 
ballooning as early as 30 seconds post-euthanasia 
with nitrogen gas. Besides, the work of Li et al [58] 
showed that hepatocyte vacuolation occurred in rats 
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